Agoracom: Small Cap Investment - Zenith Epigenetics - 5 of 8 Sites Now Recruiting for ZEN-3694/Enzalutamid... Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

5 of 8 Sites Now Recruiting for ZEN-3694/Enzalutamid... Trial

posted on Feb 23, 2017 03:18PM

As originally posted by F6 on the Investor Village board, the ZEN-3694/Enzalutamide Trial now lists 5 of 8 study sites as recruiting. 2 sites for Virginia Oncology Associates (Hampton and Norfolk) and 1 site at Oregon Health and Science University in Portland are still isted as not yet recruiting.